SCHEMBL17015706

SCHEMBL17015706

c1ccc(-c2ccc(-n3ccc4c3ccc3c5ccccc5n(-c5ccc(-n6c7ccccc7c7ccc(-c8ccccc8)cc76)cc5)c34)cc2)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.41
KDM4E B2RXH2 1/20 0.41
ATM Q13315 1/20 0.41
MAOB P27338 1/20 0.37
HDAC4 P56524 1/20 0.36
RXRA P19793 1/20 0.36
RXRB P28702 1/20 0.36
HTR7 P34969 1/20 0.34
LIMK1 P53667 1/20 0.33
NR3C1 P04150 1/20 0.32
AKR1C4 P17516 1/20 0.32
AKR1C3 P42330 1/20 0.32
AKR1C2 P52895 1/20 0.32
AKR1C1 Q04828 1/20 0.32
DNM1 Q05193 1/20 0.32
TSPO P30536 1/20 0.32
KMT2A Q03164 2/20 0.32
IL1R1 P14778 1/20 0.32
MEN1 O00255 1/20 0.31
ALDH1A1 P00352 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17016188 0.99 L3MBTL1 (0.44) L3MBTL1KDM4EATMMAOBHDAC4
SCHEMBL17015234 0.99 L3MBTL1 (0.44) L3MBTL1KDM4EATMMAOBHDAC4
SCHEMBL17015701 0.95 L3MBTL1 (0.41) L3MBTL1KDM4EATMMAOBHDAC4
SCHEMBL17015702 0.95 L3MBTL1 (0.41) L3MBTL1KDM4EATMMAOBHDAC4
SCHEMBL17015700 0.95 L3MBTL1 (0.46) L3MBTL1KDM4EATMMAOBHDAC4
SCHEMBL17015783 0.94 KDM4E (0.39) L3MBTL1KDM4EATMMAOBHDAC4
SCHEMBL17015714 0.94 KDM4E (0.36) L3MBTL1KDM4EATMMAOBHDAC4
SCHEMBL17015711 0.94 KDM4E (0.39) L3MBTL1KDM4EATMMAOBHDAC4
SCHEMBL17015232 0.94 L3MBTL1 (0.44) L3MBTL1KDM4EATMMAOBHDAC4
SCHEMBL17015235 0.94 L3MBTL1 (0.44) L3MBTL1KDM4EATMMAOBHDAC4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9837618-B2 Compound and organic electroluminescence device including thesame DOOSAN CORPORATION (KR) 2017-12-05 US disclosed
US-9837618-B2 Compound and organic electroluminescence device including thesame DOOSAN CORPORATION (KR) 2017-12-05 US disclosed
US-20150236272-A1 NOVEL COMPOUND AND ORGANIC ELECTROLUMINESCENCE DEVICE INCLUDING THESAME DOOSAN CORPORATION (KR) 2015-08-20 US disclosed
US-20150236272-A1 NOVEL COMPOUND AND ORGANIC ELECTROLUMINESCENCE DEVICE INCLUDING THESAME DOOSAN CORPORATION (KR) 2015-08-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150236272-A1 NOVEL COMPOUND AND ORGANIC ELECTROLUMINESCENCE DEVICE INCLUDING THESAME INMT, IDO1, IDO2 L3MBTL1 533/4885KDM4E 1286/4885ATM 3623/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.